Colin Richard Green
Founder at CoDa Therapeutics (NZ) Ltd.
Profile
Colin Richard Green is the founder of OcuNexus Therapeutics, Inc. (founded in 2005) and CoDa Therapeutics (NZ) Ltd.
(founded in 2003), where he holds the title of Director.
Dr. Green is also the founder of InflammX Therapeutics, Inc. Dr. Green's former job was as a Non-Executive Director at AWE Pty Ltd.
from 1997 to 2009.
Dr. Green's education includes a doctorate degree from Auckland University, which was conferred in 1980.
Colin Richard Green active positions
Companies | Position | Start |
---|---|---|
CoDa Therapeutics (NZ) Ltd.
CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand. | Founder | 08/12/2003 |
OcuNexus Therapeutics, Inc.
OcuNexus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA. | Founder | 31/12/2004 |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | Founder | - |
Former positions of Colin Richard Green
Companies | Position | End |
---|---|---|
AWE LIMITED | Director/Board Member | 18/11/2009 |
Auckland University | Corporate Officer/Principal | - |
Training of Colin Richard Green
Auckland University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 4 |
---|---|
OcuNexus Therapeutics, Inc.
OcuNexus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA. | Health Technology |
AWE Pty Ltd.
AWE Pty Ltd. Oil & Gas ProductionEnergy Minerals AWE Pty Ltd. engages in the development and explored of oil and gas properties. Its projects includes Ande Ande Lumut Oil, BassGas, Casin Gas, Tui Area Oil, Lengo Gas, Waitsia Gas, Onshore Perth, Onshore Taranaki, and North Carnavon Basin. The company was founded by Bruce John Phillips on March 17, 1997 and is headquartered in North Sydney, Australia. | Energy Minerals |
CoDa Therapeutics (NZ) Ltd.
CoDa Therapeutics (NZ) Ltd. Pharmaceuticals: MajorHealth Technology CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand. | Health Technology |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | Commercial Services |
- Stock Market
- Insiders
- Colin Richard Green